FidoCure, a pioneering company in AI-driven precision oncology for dogs, has been granted a groundbreaking patent by the U.S. Patent and Trademark Office (USPTO). This patent, U.S. Patent No. 12036281-B2, marks a significant milestone in the development of targeted cancer therapies for dogs, potentially transforming the landscape of veterinary oncology.

FidoCure’s innovative approach uses artificial intelligence to analyze real-world veterinary clinical data, enabling the development of novel, targeted therapies for canine cancer. The newly patented treatment focuses on mutation profiling to manage bladder cancer in dogs, addressing a critical unmet need. Traditional chemotherapy and radiation therapies often prove ineffective and come with toxic side effects, making them costly and challenging for pet owners and veterinarians alike.

"Bladder cancer in dogs is an unmet need as traditional chemotherapy and radiation therapy are often ineffective, cause toxic side effects, and are expensive," said Dr. Gerald Post, One Health Chief Medical Officer at FidoCure.

The patent protects FidoCure's technology for 20 years from its priority date, ensuring that the company can continue to lead in the development of advanced cancer treatments for dogs. Co-founders Christina Lopes and Benjamin Lewis, along with other key team members, are credited as the inventors of this novel therapy.

FidoCure is not only focused on bladder cancer; the company has eight additional patents pending, covering a range of novel therapies and biomarkers aimed at improving cancer treatment outcomes for dogs. By leveraging AI, FidoCure has created the world’s largest canine cancer dataset, comprising over 2 billion data points from patients treated across a network of 1,350 veterinary clinics.

"This patent acknowledges the uniqueness of our approach, which has consistently demonstrated that it can transform outcomes for pet dogs with cancer while improving the quality of life for the patients," said FidoCure CEO Christina Lopes. "Receiving a patent is an important milestone on our mission to increase access to lifesaving treatments for pet dogs with cancer."

FidoCure’s AI-driven approach to drug development is set to revolutionize veterinary medicine by offering more effective and better-tolerated cancer therapies for dogs. The company’s commitment to improving animal health through innovation aligns with the broader One Health initiative, which seeks to enhance the interconnected well-being of people, animals, and the environment.

For more information about FidoCure and its mission to transform cancer care for dogs, visit www.fidocure.com.